Please login to the form below

Not currently logged in
Email:
Password:

dexmedetomidine

This page shows the latest dexmedetomidine news and features for those working in and with pharma, biotech and healthcare.

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

BXCL501 – the company’s orally dissolving, thin film formulation of dexmedetomidine – has been assessed as part of a pivotal phase 3 TRANQUILITY programme.

Latest news

  • Cancer pain: opioids set to dominate Cancer pain: opioids set to dominate

    Sublingual and transdermal formulations of dexmedetomidine are undergoing clinical development with Recro Pharma for the adjunctive management of pain. ... In clinical trials, dexmedetomidine was well tolerated. Pierre Fabre is developing befiradol, a

  • Common ICU drug blocks cardiovascular effects of cocaine

    Precedex (dexmedetomidine), which is manufactured by US-based Orion, was found to lower the heart rate and blood pressure in a clinical trial involving 22 volunteers who had taken a small ... The study authors said further research was needed to see if

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....